Epclusa

sofosbuvir/velpatasvir (SOF/VEL)

FDA approved for HIV/HCV co-infection
Genotype
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

DOSE
One tablet once daily, usually for 12 weeks, with or without food. See treatment table at positivelyaware.com/epclusa.

Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Dosage for children may be reduced based on body weight (see below). Ribavirin may be added or treatment duration extended in patients with decompensated cirrhosis. The brand name is dispensed in a bottle; the authorized generic is in a blister pack. The authorized generic was created to help lower cost and has identical ingredients as the brand name.

Take the missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.

Black Box Warning

Before starting treatment with any direct-acting antiviral (DAA), including Epclusa, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could get worse or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation on page 33 for more information and consult your medical provider.

Epclusa dosing

Body weight

Dosing of Epclusa

Epclusa daily dose

More than 66 pounds (30 kg)

One 400 mg/100 mg tablet once daily

400 mg/100 mg per day

37.5 to 66 pounds (17–30 kg)

One 200 mg/50 mg tablet once daily

200 mg/50 mg per day

Manufacturer

brand: Gilead Sciences; authorized generic: Asegua Therapeutics LLC

AWP

brand: $29,904 / month
authorized generic: $9,600 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information